Inclusion Criteria

Inclusion criteria:

- Objectively confirmed VTE

- Initiation of enoxaparin treatment within Day 0-10 after diagnosis of VTE:

- Outpatients who will be treated with enoxaparin + VKA in combination are permitted to
receive initial treatment other than enoxaparin for a maximum of 48 hours or 2
treatment doses preceding entry into the study

- Outpatients on enoxaparin monotherapy are permitted to receive up to 10 days of
treatment other than enoxaparin preceding entry into the study.

Exclusion criteria:

- Medical or psychiatric disorders associated with altered cognition or mentation that
precludes understanding of the informed consent process.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.